Stay up to date with notifications from The Independent

Notifications can be managed in browser preferences.

EU demands AstraZeneca supply bloc with vaccine doses produced in UK

EU says it is yet to make breakthrough in talks with British-Swedish drug maker as tensions rise over vaccine

Samuel Osborne
Wednesday 27 January 2021 17:07 EST
Comments
EU threatens export controls on Covid vaccines

Your support helps us to tell the story

From reproductive rights to climate change to Big Tech, The Independent is on the ground when the story is developing. Whether it's investigating the financials of Elon Musk's pro-Trump PAC or producing our latest documentary, 'The A Word', which shines a light on the American women fighting for reproductive rights, we know how important it is to parse out the facts from the messaging.

At such a critical moment in US history, we need reporters on the ground. Your donation allows us to keep sending journalists to speak to both sides of the story.

The Independent is trusted by Americans across the entire political spectrum. And unlike many other quality news outlets, we choose not to lock Americans out of our reporting and analysis with paywalls. We believe quality journalism should be available to everyone, paid for by those who can afford it.

Your support makes all the difference.

The European Union has demanded AstraZeneca supply the bloc with more doses of its Covid-19 vaccine from two of its plants in Britain.

It comes amid a shortfall in vaccines as a result of AstraZeneca and Pfizer both announcing delivery holdups in recent weeks.

"UK factories are part of our advanced purchase agreement and that is why they have to deliver," the EU’s health commissioner, Stella Kyriakides, told a news conference on Wednesday, noting that two of the four factories from which AstraZeneca has committed to providing vaccines to the EU are in Britain.

"We reject the logic of first come, first served," Ms Kyriakides said. "That may work at the neighborhood butchers, but not in contracts and not in our advance purchase agreements. There's no priority clause in the advanced purchase agreement."

Ms Kyriakides said later on Wednesday the EU and AstraZeneca had failed to make a breakthrough in talks over vaccine deliveries.

“We regret the continued lack of clarity on the delivery schedule,” she said in a tweet, adding the EU was requesting a clear plan from AstraZeneca for the rapid delivery of the vaccine doses the bloc has reserved for the first quarter.

Boris Johnson has said it would have been a “great pity” if the UK had stayed in the EU’s vaccine programme rather than set up its own plan. "I do think that we've been able to do things differently, and better, in some ways," the prime minister said in parliament.

AstraZeneca, which partnered with Oxford University to develop its vaccine, said last week it would cut supplies to the EU in the first quarter to 31 million doses from 80 million due to reduced yields because of production issues at a Belgian factory.

The EU has been pushing AstraZeneca for a week to revise these cuts and said it expected the company to deliver the full amount on time, though it is unclear how it can force the company to deliver the agreed amounts.

Pascal Soriot, the French chief executive of AstraZeneca, told Italian newspaper La Repubblica on Tuesday that the EU contract was based on a best-effort clause and did not commit the company to a specific timetable for deliveries.

"Our contract is not a contractual commitment," Mr Soriot said. "It's a best effort. Basically we said we're going to try our best, but we can't guarantee we're going to succeed. In fact, getting there, we are a little bit delayed."

Mr Soriot said vaccines meant for the EU were produced in four plants in Belgium, the Netherlands, Germany and Italy.

But EU Commission officials claimed on Wednesday that under the contract, the company had also committed to providing vaccines from its two factories in Britain.

They added that the firm had not provided sufficient explanations on why doses could not be shipped from stocks at factories which experienced no production problem, such as those in Britain.

It comes as a factory in Wales that produces AstraZeneca’s vaccine was partially evacuated on Wednesday after it received a suspicious package and police sent a bomb disposal unit to deal with the incident.

Additional reporting by agencies

Join our commenting forum

Join thought-provoking conversations, follow other Independent readers and see their replies

Comments

Thank you for registering

Please refresh the page or navigate to another page on the site to be automatically logged inPlease refresh your browser to be logged in